← Capricor Therapeutics, Inc. (CAPR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Capricor Therapeutics, Inc. (CAPR)
Pharmaceutical Preparations · market cap $514M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
5
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Capricor Therapeutics (CAPR) is a ~$1.18B market cap cell therapy company with 160 employees whose lead asset, CAP-1002 (deramiocel), is in Phase 3 development for Duchenne Muscular Dystrophy (DMD) under orphan drug and fast-track designations. The company is pre-revenue in its core business (2025 net revenue $0M vs. $105M net loss), carries $105.4M in cash against roughly 10.8 months of runway, and faces a heavy short interest of 25.5% of float alongside elevated dilution risk.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CAP-1002 | Phase 3 | Duchenne Muscular Dystrophy |
| CAP-2003 | Phase 2 | COVID-19 Cardiac |
| Cenderitide | Phase 2 | Heart Failure |
| Allogeneic Cardiosphere-Derived Cells (CAP-1002) | Phase 2 | Duchenne Muscular Dystrophy |
| Deramiocel (CAP-1002) | Phase 3 | Duchenne Muscular Dystrophy |
Price & technical context
3-month
-60.2%
6-month
-72.2%
12-month
+12.0%
52-wk range
$3.85–$35.34
vs 50-day MA
+15.4%
vs 200-day MA
-60.7%
Realized vol
216.5%
Max drawdown
-89.1%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CAPR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.